Medical Treatment in Ectopic Tubal Pregnancy

• Status: Completed
• Trial end date: 2021-07-30
• Target enrollment: 0
• Participant gender: Female

Summary

Ectopic pregnancy (EP) is estimated to be responsible for approximately 20% of all pregnancy-related mortality and 46% early pregnancy mortality.1 Hemodynamically stable women with EP are frequently managed with methotrexate (MTX) while multiple protocols like fixed multiple doses, single-dose as well as two-dose regimens have been in practice for treating EP, but no consensus exists regarding the optimum dosage regimen.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nishtar Medical University
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Diagnosis of tubal ectopic pregnancy.

• Pre-treatment beta-human chorionic gonadotrophin (β-hCG) level below 1500 mIU/ml.

• Gestational sac with largest diameter as 4cm.

• Willing to take methotrexate treatment.

• Willing to follow up.

Exclusion Criteria:

• Heterotrophic pregnancy

• Persistent tubal pregnancy

• Embryonic cardiac motion

• Suspected tubal rupture

• Past history of harmful effects of methotrexate treatment on organ functions.